quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:54:21·43d
INSIDERFiling
Phathom Pharmaceuticals Inc. logo

SEC Form 4 filed by Phathom Pharmaceuticals Inc.

PHAT· Phathom Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • PHAT
    Phathom Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 27UpdateBarclays$18.00
  • Dec 12UpdateRaymond James$28.00
  • Dec 9UpdateBarclays$16.00
  • Feb 14UpdateCantor Fitzgerald$23.00
  • May 3UpdateStifel$24.00
  • Jan 5UpdateNeedham$26.00

Related

  • PR3d
    Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
  • SEC16d
    SEC Form DEFA14A filed by Phathom Pharmaceuticals Inc.
  • SEC16d
    SEC Form DEF 14A filed by Phathom Pharmaceuticals Inc.
  • PR17d
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
  • SEC27d
    SEC Form S-8 filed by Phathom Pharmaceuticals Inc.
  • ANALYST27d
    Phathom Pharmaceuticals upgraded by Barclays with a new price target
  • SEC42d
    SEC Form SCHEDULE 13G filed by Phathom Pharmaceuticals Inc.
  • PR50d
    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022